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Currently, treatment for Alzheimer’s disease (AD) focuses on the cholinergic hypothesis and provides limited symptomatic effects.
Research currently focuses on other factors that are thought to contribute to AD development such as tau proteins and Aβ deposits,
and how modiﬁcation of the associated pathology affects outcomes in patients. This systematic review summarizes and appraises the
evidence for the emerging drugs affecting Aβ and tau pathology in AD.
5 March 2015METHODS
A comprehensive, systematic online database search was conducted using the databases ScienceDirect and PubMed to include original
research articles. A systematic review was conducted following a minimum set of standards, as outlined by The PRISMA Group [1]. Speciﬁc
inclusion and exclusion criteria were followed and studies ﬁtting the criteria were selected. No human trials were included in this review. In
vitro and in vivo AD models were used to assess efﬁcacy to ensure studied agents were emerging targets without large bodies of evidence.RESULTS
The majority of studies showed statistically signiﬁcant improvement (P < 0.05) of Aβ and/or tau pathology, or cognitive effects. Many
studies conducted in AD animal models have shown a reduction in Aβ peptide burden and a reduction in tau phosphorylation post-
intervention. This has the potential to reduce plaque formation and neuronal degeneration.CONCLUSIONS
There are many emerging targets showing promising results in the effort to modify the pathological effects associated with AD. Many
of the trials also provided evidence of the clinical effects of such drugs reducing pathological outcomes, which was often demonstrated
as an improvement of cognition.Introduction
AD is an irreversible neurodegenerative disease that has crip-
pling effects on the nervous system and consequently on daily
life. It is the most common form of dementia, accounting for
almost two thirds of dementia cases in the United Kingdom;
affecting around 520 000 people in 2012 [2].
AD pathophysiology
The underlying mechanisms of AD are still unconﬁrmed
but the aggregation of tau proteins, Aβ deposits anddecreased concentrations of acetylcholine are three of
the current factors being considered to aid the production
of new targets for AD therapies [3].Tau pathophysiology Tau is a protein, known as a
microtubule-associated protein (MAP), and an integral part
of neuronal stability as it helps to maintain the
microtubules that form part of the neuron cytoskeleton. Tau
is encoded by a gene located on chromosome 17q21 and
undergoes splicing to produce various isoforms [4].acol / 80:2 / 221–234 / 221
S. West & P. BhugraIn AD, abnormal phosphorylation/hyperphosphorylation
occurs causing tau to have a decreased afﬁnity for microtu-
bules, which results in the movement of tau proteins from
themicrotubule to the intracellular neuronal space. This leaves
the microtubule unstable and it consequently starts to col-
lapse. The hyper-phosphorylated free tau proteins move
down the axon fromwhere they dissociated from themicrotu-
bules and self-aggregate in the neuron cell body forming neu-
roﬁbrillary tangles. This impairs axonal transport leading to
dysfunction of the synapse and ultimately neuronal death [4].
The functions of the tau protein are regulated by various
kinases. Glycogen synthase kinase 3 (GSK3) plays a role in
the hyperphosphorylation of tau which is a key feature in
AD. Phosphorylation of tau by GSK3 occurs at the microtu-
bule binding domain, therefore reducing the extent to
which tau can bind to microtubules and hence causes disso-
ciation between the tau proteins and the microtubules [5].
Amyloid precursor protein and amyloid β pathophysiology Aβ
peptides are produced and released during normal synaptic
activity in the brain via the catabolism of the amyloid
precursor protein (APP) by secretases in the neuronal
membrane. It is thought that an excess amount of Aβ42
(which is the most toxic and amyloidogenic form of the
peptide) is a key cause of cellular damage in AD. Aβ42 is
produced during the second step of APP catabolism
when the γ-secretase acts on the β-secretase product
from step 1 of the catabolism [6]. In a healthy brain, these
fragments would be broken down and eliminated from
the body. However in AD they are not sufﬁciently broken
down and accumulate to form one of the typical
characteristics of AD, amyloid plaques.
There are currently only four drugs recommended in
the United Kingdom by the National Institute for Health
and Care Excellence [7]; three of which are acetylcholin-
esterase inhibitors (AChEi) and one a novel agent acting
on the glutaminergic system, memantine.
This systematic review was conducted with the aim of
summarizing, comparing and contrasting the evidence for
the emerging targets and corresponding agents to treat
AD. It focuses on the tau hypothesis and the amyloid hy-
pothesis of AD to provide an overall review of the two most
researched but undeveloped areas of AD therapeutics.Methods
The PRISMA Guidelines [1] were followed in the search
for relevant literature and the writing of this review to
ensure an evidence-based minimum set of standards
was fulﬁlled when compiling and presenting the evi-
dence relevant to answer the research question.
Criteria for selecting studies
Types of studies Studies included in this review included
original research articles published by the corresponding222 / 80:2 / Br J Clin Pharmacolresearchers and did not include any review articles to ensure
that studies were assessed individually and compared
against the inclusion criteria for this speciﬁc review. This also
prevented using another author’s conclusions in the report.
The studies must have been published between the years
of 2011–2014 and be assessing the use of novel agents
targeting Aβ or tau for the treatment of AD in order to
produce a systematic review of the most up-to-date,
relevant trials. Articles were also only considered if they
were written in the English language. Both published
articles and accepted manuscripts were included.
Participants
No human trials were included in this study as it focused
solely on the emerging drugs and targets for AD and there-
fore only used research conducted in vitro or in animal
studies. This ensured the information gathered was the
most recent and was not focused on well-established trial
agents that have large bodies of evidence. The animals
involved in the studies in this report were transgenic mice
and rats, therefore providing a suitable AD model for the
novel agents to be tested upon.
Interventions
Any agent targeted towards either Aβ or tau used in the
treatment of AD was classed as an intervention regardless
of dose. However, the drug must be used in an AD model
and not on healthy tissue in vitro or in healthy animals
otherwise the results cannot be compared with AD itself.
Outcome measures
Outcomes were measured as a change in the pathologi-
cal features of AD, for example, a reduction in tau aggre-
gation or a stabilization in microtubules, and as a change
in cognition if conducted in animals. As the studies were
not conducted in humans, the level of cognition in terms
of recognized scoring systems, such as the change in
score of the Mini Mental State Examination could not
be measured and was therefore based on other methods,
for example, the Morris water maze test.
Bias
Risk of bias The risk of bias was assessed, using the ‘Model
Quality Assessment Instrument for Animal Studies’ [8] as
outlined in their review of assessment tools for published
animal studies, for all studies included in this review. Five
main types of bias were assessed with a decision made as
to the risk of bias. Bias was assessed as low risk, high risk or
unclear risk if there was insufﬁcient evidence to make a
conclusion.
Information sources
A systematic online database search was conducted in
January 2014 using the online databases ScienceDirect
and PubMed to include original research articles only.
The databases were last searched on March 2, 2014.
Table 1
ScienceDirect and PubMed electronic searches are compared
ScienceDirect PubMed




(tau OR Aβ OR amyloid
or APP)) in all ﬁelds
((‘Alzheimer Disease/drug therapy’ [Mesh]) AND
‘tau proteins’ [Mesh]) AND
‘Amyloid beta-Peptides’ [Mesh]
Reﬁned to: Articles Limited to: Journal articles and in vitro
Years: 2011 to present Species: Other animals
Returned 567 results Language: English
Years: 01/01/2011 – 02/03/2014
Returned 42 results
Emerging targets for Aβ and tau in Alzheimer’s disease: a systematic reviewSearch
The full electronic search strategies are outlined in
Table 1.Results
Data collection process
Study selection Studies were selected from the initial
combined 608 results (after removing duplicates) based onFigure 1
Algorithm of the method followed to identify the studies to be included in thetheir title relevance and being original research articles.
Fourteen studies were selected from the PubMed MeSH
database search and the others excluded based on
irrelevant titles. Irrelevance was deﬁned as any study not
being directly associated with tau proteins or Aβ/amyloid
beta-peptides and therefore many results were not
included as they were based on AChEis or the cholinergic
hypothesis of AD. Forty-three articles were deemed
relevant, based on title, from the ScienceDirect database
search. A total of 31 studies were included in this
systematic review (Figure 1).
Study characteristics
Characteristics of included studies The studies included
in this systematic review were assessed and described
in terms of the type of study, the intervention strategy
used and outcomes/results speciﬁcally in terms of Aβ
pathology, tau pathology and cognitive effects (Table 2).
Methodological quality summary
The results for the risk of bias assessment are summa-
rized in Table 3.
Effects of interventions
The agents studied in the selected trials were classiﬁed
based on their putative mechanism of action and their
effects on AD pathology into the following groups,review (adapted from The PRISMA Group [1])
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Table 3
Summary of author's risk of bias decisions
Key: Low Risk of Bias ; Unclear Risk of Bias ; High Risk of bias
S. West & P. Bhugraanti-amyloidogenic agents, neuro-protective agents, GSK-3β
inhibitors and miscellaneous agents.Anti-amyloidogenic agents
All of the anti-amyloidogenic agents chosen for inclusion
into this review showed improvement in amyloid precur-
sor protein processing, with three studies demonstrating
a signiﬁcant reduction in Aβ levels (P < 0.05) [9–11].
Five of the studies also provided evidence of reduced230 / 80:2 / Br J Clin Pharmacoltau phosphorylation despite targeting the amyloid pa-
thology associated with AD [9–13], with the study con-
ducted by Wang et al. [13] demonstrating that PTI-125
suppressed the phosphorylation of tau at all three of
the tau phosphorylation sites. Vepsäläinen et al. [14] ex-
amined the effects of the anthocyanin rich diet on the
levels of tau phosphorylation but they observed no
changes. Cognition was improved, but not necessarily
statistically signiﬁcantly, following the dose and dura-
tion of the given investigations [10, 12, 14, 15].Neuro-protective agents
Cognition was improved signiﬁcantly in the three studies
that measured this outcome, P = 0.03, P < 0.001, P =
0.0001, as shown by Barron et al. [16], Lo et al. [17] and
O’Hare et al. [18], respectively. Aβ pathology was im-
proved signiﬁcantly in all studies with the exception of
Lo et al. [17] who experience no change following inter-
vention. Ramalho et al. [19] reported that TUDCA signiﬁ-
cantly prevented Aβ-induced cell death (P < 0.05) and
Yang et al. [20] reported a signiﬁcant decrease in Aβ
plaque area following intervention (P < 0.05).GSK-3β inhibitors
All of the outcomes measured in the studies showed an
improvement, whether this be in Aβ pathology, tau pa-
thology or in cognition. Durairajan et al. [21] showed a
signiﬁcant improvement in the area occupied by Aβ de-
posits (P< 0.001) showing potential for disease modiﬁca-
tion. A signiﬁcant improvement (P < 0.01) was seen in
the levels of tau phosphorylation in the study of GAO by
Farr et al. [22]. A signiﬁcant improvement in cognition
was also seen in two studies [21, 22].Miscellaneous agents
Of the seven studies that investigated the effects of their in-
tervention on Aβ pathology, all observed changes in the
levels of Aβ but only two reported a statistically signiﬁcant
difference in their treatment groups vs. controls [23, 24].
Sung et al. [25] also reported a signiﬁcant change in Aβ
pathology but only in terms of Aβ1-40 and not the toxic
species Aβ1-42. Tau phosphorylation was signiﬁcantly
decreased in three studies [25–27], with Sung et al. [25]
reporting that it was signiﬁcantly reduced speciﬁcally at
the Thr181 site of tau phosphorylation. Corona et al. [23] re-
ported that their intervention had no effect on the phos-
phorylation of tau and similarly, Nikkel et al. [28] stated
that their intervention did not affect tau when it was given
alone. The majority of the studies that tested their subjects
for changes in cognition reported a signiﬁcant change in
treatment groups when compared with control groups.
Two of these produced non-signiﬁcant changes in cogni-
tion [24, 29] and Sierksma et al. [30] reported that their in-
tervention, GEBR-7b, had no effect on cognition.
Emerging targets for Aβ and tau in Alzheimer’s disease: a systematic reviewDiscussion
Anti-amyloidogenics, neuro-protectants, GSK-3β inhibitors
and the various miscellaneous agents chosen for inclusion
in this systematic review, generally, signiﬁcantly improved
the Aβ pathology, tau pathology and cognitive effects asso-
ciated with AD. Many different drug targets were
established in the trials through the use of agents to target
the various pathological manifestations implicated in AD.
Summary of evidence
Altering tau pathology Tau hyperphosphorylation has
signiﬁcant effects on neuronal degeneration and cell
death as it affects the cytoskeleton due to dissociation
of the tau protein from microtubules. The prevention of
hyperphosphorylation has the potential to prevent
neuroﬁbrillary tangles associated with AD pathology
and also slow/prevent damage to neurons that is
caused by dissociation of hyperphosphorylated tau.
Many of the studies selected for this review report that
they have observed a signiﬁcant reduction in tau
phosphorylation during the study of their novel agent. It
is important to note here that although results such as
these seem both highly beneﬁcial and interesting, the AD
model used must be taken into account, as not all AD
animal models actually possess traits that would de-
velop into neuroﬁbrillary tangles from excessive tau
hyperphosphorylation. For example, Shytle et al. [11]
used the Tg2576 AD model which displays no evidence
of neuroﬁbrillary tangles yet it was reported in their study
that their intervention, HSS-888, decreased the soluble
fractions of phosphorylated tau in the examined brain
homogenates. It must be considered that these are two
different outcomes with potentially different clinical
outcomes. There is no evidence here that there is an
effect on neuroﬁbrillary tangles, due to a reduction in
tau hyperphosphorylation, as the Tg2576 mice do not
exhibit this trait.
Altering Aβ pathology
Reduction in Aβ burden Reducing the amount of toxic am-
yloid beta peptides present in the brain is thought to be a
key method of reducing AD pathology and preventing the
Aβ associated cellular damage. Many studies conducted in
animal AD models have shown a reduction in Aβ peptide
burden in the brains of animals following intervention,
which has the potential to prevent plaque formation.
The results from the three studies speciﬁcally investi-
gating a reduction in Aβ1-40 and/or Aβ1-42 levels in an-
imal AD models [9, 14, 31], were very promising but it
has to be remembered that a mouse model of AD is still
very different from AD in humans. The clearance rate of
amyloid-β peptides in mice is at least ﬁve times greater
than that of the human brain and how the rate of degra-
dation compares between a mouse brain and a human
brain is still unknown. Therefore the applicability of theseresults to progression into clinical trials has to be
questioned [32].Prevention of Aβ accumulation Perhaps one of the most
promising aspects of AD treatment is the prospect of
prevention of Aβ peptide accumulation. If the disease
could be prevented by treatment before the disease has
progressed, patients at high risk for the disease could be
identiﬁed and given prophylactic treatment to prevent
the disease establishing or progressing any further.
Although the small amount of evidence for prevention
was promising, it would be difﬁcult to transfer this into
practical use as the risk factors for AD and the potential of
these risk factors to cause AD is still not fully understood.
Therefore, it would be difﬁcult to know when to initiate
such a treatment to gain its full effects. This would also be
something that would be difﬁcult to study in human
subjects in anything other than a retrospective study. It
would also be difﬁcult to identify patients at risk of AD
and then determine whether the onset/lack of onset of
AD was due to the treatment.Cognitive effects Reporting the changes in cognition in
animal studies relies on the evidence of specialist tasks
that test spatial learning, spatial working memory and
short/long term memory. Anxiety levels are often also
reported, as anxiety can be one of the early signs
associated with AD. Obviously, it is difﬁcult to compare
the results of such tests to the cognition of humans.
However studies such as those discussed highlight the
potential beneﬁts of the novel agents on cognition.
Generally, cognition was improved by many of the
agents for the emerging targets. Of the 19 studies that
investigated the effects of their agent on cognition,
only two reported that there were no changes in
cognition [23, 30], and 10 reported signiﬁcant changes
demonstrating an improvement across all drug classes
[12, 16–18, 21, 22, 27, 33–35].
Many of the studies included in this systematic review
used the Morris water maze test, a specially designed test
aimed to study spatial learning and memory of the
subject, as the animal must ﬁnd the platform without any
sensory clues. There are no olfactory or sensory stimuli to
aid identiﬁcation of where the hidden platform resides.
The use of the Morris water maze test can examine learning
and memory with more reliable results than the use of the
T-maze test. Spontaneous alternation in the T-maze is a 50 :
50 chance. Therefore it has a greater potential to be due to
chance rather than due to effects on spatial working mem-
ory [40]. However, the Morris water maze test was designed
for use in rats as they are naturally accustomed to water,
but many studies use mice as their test subjects which
therefore has the potential to confound results. These fac-
tors must be taken into account when establishing the reli-
ability of studies.Br J Clin Pharmacol / 80:2 / 231
S. West & P. BhugraLimitations
There are limitations in this review, the main limitation
being the lack of information disclosed regarding bias.
The risk of bias was determined to be high in many stud-
ies, which indicated there was a potential for biased
reporting as all of the information, required to clearly
state all possible factors of bias, could not be established.
Simple factors could have been speciﬁed to reduce the
risk of bias, such as the type of food used and how this
differed between treatment and control groups.
The results of this study are also limited by the fact that
all of the studies were conducted either in vitro or in vivo
using animals as test subjects. This prevents the results
from being easily transferrable to human studies. Obviously
this was an expected limitation as a drug target would not
be classed as an emerging target if it was established
enough to be being tested in human subjects.
The results reported in the trials were often signiﬁcant
in terms of the studies’ particular outcomes. However
their clinical signiﬁcance remains unknown.Conclusion
It is clear that there are many potential drug targets for
AD that are still yet to be fully explored as many of the
novel agents discussed are showing great potential for
reducing the pathological and cognitive effects associ-
ated with AD. More good quality animal studies, with a
signiﬁcantly lower risk of bias, would be needed to estab-
lish the true extent of the effects of each agent before
considering investigation in human subjects. It would
also be beneﬁcial to increase the duration of study, be-
cause despite AD being a chronic progressive disease,
many of the in vivo animal studies were conducted over
a short period of time therefore preventing the full
extent of the agents’ effects to be identiﬁed. Studies
involving human subjects would pose an interesting pro-
gression to the current research, to establish whether the
signiﬁcant effects on Aβ/tau pathology and cognition
could be repeated.Competing Interest
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